Overview

A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors

Status:
Completed

Trial end date:
2014-06-01

Target enrollment:

Participant gender:

Summary

This is a study to evaluate the effectiveness of erlotinib compared with a placebo sugar pill following complete surgical removal of the tumor with or without chemotherapy after surgery in Stage IB-IIIA NSCLC patients.

Phase:

Phase 3

Details

Lead Sponsor:

OSI Pharmaceuticals

Treatments:

Erlotinib Hydrochloride